CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab (CENDIFOX)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05121038 |
|
Recruitment Status :
Recruiting
First Posted : November 16, 2021
Last Update Posted : November 24, 2021
|
Sponsor:
Anup Kasi
Collaborator:
Cend Therapeutics Inc.
Information provided by (Responsible Party):
Anup Kasi, University of Kansas Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a phase IB/IIA trial to ensure the safety of CEND-1 in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Colon Cancer Pancreas Cancer Digestive Cancer | Drug: CEND-1 Drug: Panitumumab Drug: Folfirinox | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 50 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1B/2A Trial Of CEND-1 In Combination With Neoadjuvant FOLFIRINOX Based Therapies In Pancreatic, Colon And Appendiceal Cancers (CENDIFOX) |
| Actual Study Start Date : | October 20, 2021 |
| Estimated Primary Completion Date : | September 2023 |
| Estimated Study Completion Date : | September 2025 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Panitumumab
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort 1 Pancreatic Cancer
Biopsy for tissue immune profile if archived tissue not available. Folfirinox infusion for 3 cycles followed by a repeat biopsy for a second tissue immune profiling. Folfirinox plus CEND1 infusion for 3 cycles. Seventy-two hours after last infusion participant will have surgery.
|
Drug: CEND-1
The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4). Drug: Folfirinox FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order. All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).
then • Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home. Other Name: Oxaliplatin,Leucovorin,Irinotecan,Fluorouracil |
|
Experimental: Cohort 2 Peritoneal Mets
Biopsy for tissue immune profile if archived tissue not available. Folfirinox plus Panitumumab (if RAS/BRAF) infusion for 3 cycles followed by a repeat biopsy for a second tissue immune profiling. Folfirinox plus Panitumumab (if RAS/BRAF positive) and CEND1 infusion for 3 cycles. Seventy-two hours after last infusion participant will have surgery.
|
Drug: CEND-1
The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4). Drug: Panitumumab Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called "RAS/BRAF wild type" will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX. Drug: Folfirinox FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order. All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).
then • Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home. Other Name: Oxaliplatin,Leucovorin,Irinotecan,Fluorouracil |
|
Experimental: Cohort 3 Oligomets Colon Cancer
Biopsy for tissue immune profile if archived tissue not available. Folfirinox plus Panitumumab (if RAS/BRAF) infusion for 3 cycles followed by a repeat biopsy for a second tissue immune profiling. Folfirinox plus Panitumumab (if RAS/BRAF positive) and CEND1 infusion for 3 cycles. Seventy-two hours after last infusion participant will have surgery.
|
Drug: CEND-1
The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4). Drug: Panitumumab Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called "RAS/BRAF wild type" will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX. Drug: Folfirinox FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order. All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).
then • Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home. Other Name: Oxaliplatin,Leucovorin,Irinotecan,Fluorouracil |
Primary Outcome Measures :
- Drug Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: 24 months ]Adverse Events : Counts and proportions of grade 3 -5 Adverse Events
Secondary Outcome Measures :
- Overall survival (OS) [ Time Frame: 48 months ]Overall survival (OS) will be reported using median survival time along with a 90% confidence interval
- Disease-free survival (DFS) [ Time Frame: 48 months ]Disease-free survival (DFS) will be reported using median survival time along with a 90% confidence interval
- Overall response rate (ORR) [ Time Frame: 24 months ]Overall response rate (ORR) will be reported as a proportion with 90% confidence interval.
- RO resection rate (RORR) [ Time Frame: 24 months ]RO resection rate (RORR) will be reported as a proportion with 90% confidence interval.
- Pathological response rate (PCR) . [ Time Frame: 24 months ]Pathological response rate (PCR) will be reported as a proportion with 90% confidence interval.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 1
- One or more lesions evaluable on MRI, positive emission tomography (PET)/CT, or dedicated CT scan according to RECIST v1.1
- Patients with histologically confirmed pancreatic ductal adenocarcinomas, colorectal and appendiceal adenocarcinomas
- For cohort 1: Resectable Pancreatic Cancer: No evidence of distant metastasis and tumor mass showing no extension to superior mesenteric artery (SMA) and hepatic artery. There must be clear fat plane between SMA and celiac axis. Patent superior mesenteric vein (SMV/portal vein (PV) with no distortion of venous architecture. Please refer to 2021 NCCN PDAC Guidelines
- For cohort 1: Borderline Resectable Pancreatic Cancer: defined as localized cancer with 1 or more of the following features: "a) an interface between the primary tumor and superior mesenteric vein (SMV)-portal vein (PV) measuring 180o or greater of the circumference of the vein wall, and/or b) short-segment occlusion of the SMV-PV with normal vein above and below the level of obstruction that is amenable to resection and venous reconstruction and/or c) short segment interface of any degree between tumor and hepatic artery with normal artery proximal and distal to the interface that is amenable to resection and arterial reconstruction and/or d) an interface between the tumor and SMA or celiac trunk measuring less than 180o of the circumference of the artery wall. Please refer to 2021 National Comprehensive Cancer Network (NCCN) Pancreatic Ductal Adenocarcinoma (PDAC) Guidelines
- For cohort 2: Peritoneal Metastases due to Colorectal Cancer or Invasive Adenocarcinoma of the Appendix
- For cohort 3: Oligometastatic colorectal cancer: resectable metastases as determined by multidisciplinary evaluation. Patients with bilobar liver metastases or oligometastatic liver and lung metastases that requires resection of one or more metastases are also allowed
- Eligible for treatment with FOLFIRINOX with or without panitumumab
- Life expectancy of at least 3 months
- Adequate archival tissue from prior biopsy for biomarker evaluation or willingness to undergo biopsy before treatment starts and on treatment
- Medically fit to undergo complex major abdominal surgery at end of study treatment
- Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to enrollment
- Adequate organ function
Exclusion Criteria:
- Simultaneously enrolled in any therapeutic clinical trial
- Concurrent use of any other anti-cancer therapy, including chemotherapy, targeted therapy, immunotherapy, or biological agents
- Prior chemotherapy or any other investigational agents for the treatment of cancer within 2 years prior to enrollment on this study
- Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements
- Is pregnant or breastfeeding
- Has a known allergic reaction to any excipient contained in the study drug formulation
- Active Grade 3 (per the NCI CTCAE, Version 5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment
- New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG
- Known infection with HIV, hepatitis B, or hepatitis C
- Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator
- Participants with known brain metastases. Screening for brain metastases with head imaging is not required
-
History of prior or current synchronous malignancy, except:
- Malignancy that was treated with curative intent and for which there has been no known active disease for >3 years prior to enrollment
- Curatively treated non-melanoma skin cancer, cervical cancer in situ, or prostatic intraepithelial neoplasia, without evidence of prostate cancer
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05121038
Contacts
| Contact: KUCC Navigation | 9135883671 | kucc_navigation@kumc.edu |
Locations
| United States, Kansas | |
| The University of Kansas Cancer Center (KUCC) | Recruiting |
| Fairway, Kansas, United States, 66205 | |
| Contact: KUCC Navigator 913-588-3671 kucc_navigation@kumc.edu | |
| The University of Kansas Cancer Center, Westwood Campus | Recruiting |
| Kansas City, Kansas, United States, 66205 | |
| Contact: KUCC Navigation 913-588-3671 kucc_navigation@kumc.edu | |
| United States, Missouri | |
| The University of Kansas Medical Center | Recruiting |
| North Kansas City, Missouri, United States, 64116 | |
| Contact: Nurse Navigator 913-945-7552 ctnursenav@kumc.edu | |
Sponsors and Collaborators
Anup Kasi
Cend Therapeutics Inc.
Investigators
| Principal Investigator: | Anup Kasi, MD | University of Kansas Medical Center |
| Responsible Party: | Anup Kasi, MD, MPH, University of Kansas Medical Center |
| ClinicalTrials.gov Identifier: | NCT05121038 |
| Other Study ID Numbers: |
IIT-2021-CENDIFOX |
| First Posted: | November 16, 2021 Key Record Dates |
| Last Update Posted: | November 24, 2021 |
| Last Verified: | November 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
Additional relevant MeSH terms:
|
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Endocrine Gland Neoplasms Pancreatic Diseases Endocrine System Diseases Leucovorin Fluorouracil Oxaliplatin Irinotecan Panitumumab Folfirinox Antimetabolites |
Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Antidotes Protective Agents Vitamin B Complex Vitamins Micronutrients Antineoplastic Agents, Immunological |